Just for the fun of it, and since we did not include it in our Outlook 2024, I decided to have a look at what experts are saying concerning mushrooms, cannabis, and hemp. After all, recreational and medical alternatives as investments, have been huge underperformers, and are a bit of a legend in their own minds.
As I looked around, I saw predictions for increasing sales of pre-rolls, reduction of THC percentages in products to encourage more sales, improving medical benefits and the continuing rise of mushrooms as contenders. What caught my eye, though, was this:
“In 2024, hemp beverages will do more to normalize cannabis in the minds of the consumer than any other form factor.” — Kenny Morrison, Founder, CQ
CQ is a beverage company that makes hemp-infused juices and sodas.
The cans are fun. The message is “Crafted from the highest quality ingredients, expect a refreshing infusion of real fruit and terpene-rich cannabis for a deliciously juicy buzz.” They are not though, publicly traded.
Hemp, I mean hence, I looked up four stocks I found surprising technically and perhaps great for the new year to add to your portfolio.
Altria (MO) came up on my search for companies that sell hemp and other infused companies. Underperforming SPY, and yet experiencing an improved phase change to recovery, tells me this is one to watch.
MO spent all of 2023 under the 23-month moving average. Watch for a move over 46.00.
Anheuser-Busch InBev (BUD) looks better. Also underperforming SPY, check out that golden cross. Momentum is interesting as well, so watch this one on a weekly close over 65.00.
Molson Coors Beverage (TAP) had a huge drop from the highs last week. However, the longer-term charts look fine. Some volume and a shove back over 64.00 looks interesting.
AbbVie Inc (ABBV) looks the best right now. This is outperforming SPY and momentum is super strong. Why ABBV? Marinol, a compound known as dronabinol, is a synthetic form of THC that shows the promise of cannabis as a treatment. More importantly, is it a direct sign of traditional pharma navigating the alt treatment space. Over 155 could easily take this to 175 or beyond.
This is for educational purposes only. Trading comes with risk.
If you find it difficult to execute the MarketGauge strategies or would like to explore how we can do it for you, please email Ben Scheibe at Benny@MGAMLLC.com, our Head of Institutional Sales. Cell: 612-518-2482.
For more detailed trading information about our blended models, tools and trader education courses, contact Rob Quinn, our Chief Strategy Consultant, to learn more.
Get your copy of Plant Your Money Tree: A Guide to Growing Your Wealth.
Grow your wealth today and plant your money tree!
“I grew my money tree and so can you!” – Mish Schneider
Follow Mish on Twitter @marketminute for stock picks and more. Follow Mish on Instagram (mishschneider) for daily morning videos. To see updated media clips, click here.
Mish makes the case for Vaxcyte (PCVX) and presents the bullish case for gold in this appearance on Business First AM from November 29th.
Mish talksabout money supply, debt, the consumer, inflation and trends that could gain traction in 2024 with Nicole Petallides on Schwab Network.
On the Tuesday, November 28 edition of StockCharts TV’s Your Daily Five, Mish presents 6 stock picks with specific actionable plans.
Mish covers the technical setup for Palo Alto and how MarketGauge’s quant models found this winner on Business First AM.
Mish and Maggie Lake cover inflation, technology, commodities and stock picks in this interview with Real Vision.
Mish talks trading range, fundamentals, and how to think about commodities right now on Yahoo! Finance.
In this appearance on BNN Bloomberg, Mish covers the emotional state of oil and gold, plus talks why small caps are the key right now. She also presents a couple of picks!
Learn how to trade commodities better with Mish in this interview with CNBC Asia!
Mish and Charles Payne discuss why the small caps, now in mid range still have a chance to rally in this appearance on Fox Business’ Making Money with Charles Payne.
Mish talks about Tencent Music Entertainment on Business First AM.
Coming Up:
December 20: Outlook 2024 with StockCharts
December 22: Yahoo! Finance
December 28: Singapore Breakfast Radio
January 2: The Final Bar with David Keller, StockCharts TV
January 5: Daily Briefing, Real Vision
Weekly: Business First AM, CMC Markets
- S&P 500 (SPY): 475 resistance, 465 underlying support.
- Russell 2000 (IWM): 200 resistance and 194 support.
- Dow (DIA): Strongest index and needs to hold 370.
- Nasdaq (QQQ): 410 resistance with support at 395.
- Regional banks (KRE): 47 support, 55 resistance.
- Semiconductors (SMH): 174 pivotal support to hold this month.
- Transportation (IYT): Needs to clear these highs and hold 250.
- Biotechnology (IBB): 130 pivotal support.
- Retail (XRT): Huge gap up last 2 days of the week that now needs to hold.
Mish Schneider
MarketGauge.com
Director of Trading Research and Education
Mish Schneider serves as Director of Trading Education at MarketGauge.com. For nearly 20 years, MarketGauge.com has provided financial information and education to thousands of individuals, as well as to large financial institutions and publications such as Barron’s, Fidelity, ILX Systems, Thomson Reuters and Bank of America. In 2017, MarketWatch, owned by Dow Jones, named Mish one of the top 50 financial people to follow on Twitter. In 2018, Mish was the winner of the Top Stock Pick of the year for RealVision.
